MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive: The activation of ERK1/2 after long-term imatinib treatment is a kind of CML resistance mechanisms, therefore, combination of ERK inhibitors and imatinib has been used in IM-resistant CML (52–54).